Work

Design, synthesis and pharmacological evaluation of non-peptidergic ligands for the human CXCR3 receptor

Year: 2010
Type: dissertation
Abstract: The CXCR3 chemokine receptor was discovered in 1996 and has been shown to play an important role in several diseases, most of which are related to inflammation. This chapter describes in detail the development of small CXCR3 ligands and their therapeutic potential. Classes of CXCR3 antagonists with strikingly variable core structures have emerged. Some of these compounds have confirmed the beneficial role of CXCR3 antagonism in animal models of disease. One of the compounds, AMG 487, progressed to Phase II clinical trials but has been withdrawn due to lack of efficacy. New antagonist classes are being developed in order to reveal the full therapeutic potential of CXCR3.
Author: Storelli, S.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W1534876299
Cites: 101
Cited by:
Related to: 10